Trial Profile

A randomized , placebo-controlled, investigator sponsored clinical trial to evaluate Osanetant to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD)

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osanetant (Primary)
Indications Acute traumatic stress disorders; Post-traumatic stress disorders
Focus Therapeutic Use
Acronyms OASIS

16 Mar 2023 According to an Acer Therapeutics media release, ACER-801 did not achieve statistical significance when evaluating its ability to decrease frequency or severity of hot flashes in postmenopausal women. As a result, company is pausing ACER-801 program until company has conducted a thorough review of the full data set.
16 Mar 2023 Status changed from planning to suspended, according to an Acer Therapeutics media release.
12 Oct 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com